Dong Zhongyi, Leavenworth Jianmei W
Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Graduate Biomedical Sciences Program, University of Alabama at Birmingham, Birmingham, AL, USA.
Immunometabolism (Cobham). 2025 Jul 5;7(3):e00063. doi: 10.1097/IN9.0000000000000063. eCollection 2025 Jul.
A significant barrier to the success of adoptive cell therapies (ACTs) in cancer treatment is the inadequate persistence of T-cells following infusion. In vitro T-cell expansion is a crucial component of ACTs; therefore, preconditioning during culture may enhance their in vivo survival and therapeutic efficacy. Here, we discuss a recent article by Greg Delgoffe and colleagues that was published in in April 2025, providing evidence that pharmacologic metabolic rewiring of activated T-cells during in vitro expansion enhances their engraftment postinfusion and improves cellular immunotherapies.
过继性细胞疗法（ACTs）在癌症治疗中取得成功的一个重大障碍是输注后T细胞的持久性不足。体外T细胞扩增是ACTs的关键组成部分；因此，培养过程中的预处理可能会提高它们在体内的存活率和治疗效果。在此，我们讨论格雷格·德尔戈夫及其同事于2025年4月发表的一篇近期文章，该文章提供了证据表明，在体外扩增过程中对活化T细胞进行药理学代谢重编程可提高其输注后的植入率，并改善细胞免疫疗法。
